Jamjoom Pharmaceuticals Factory Company (TADAWUL: 4015)

Market Cap	10.44B
Revenue (ttm)	1.27B
Net Income (ttm)	349.40M
Shares Out	70.00M
EPS (ttm)	4.99
PE Ratio	29.89
Forward PE	25.04
Dividend	3.20 (2.14%)
Ex-Dividend Date	Aug 18, 2024

Volume	84,650
Open	149.40
Previous Close	149.20
Day's Range	149.00 - 153.00
52-Week Range	104.60 - 202.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About Jamjoom Pharmaceuticals Factory Company

Jamjoom Pharmaceuticals Factory Company manufactures and markets pharmaceutical products in the Kingdom of Saudi Arabia and internationally. The company offers products human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer, and acidity, as well as various skin infections, cancer diseases, eye drops and ointments, and cosmeceuticals. Jamjoom Pharmaceuticals Factory Company was founded in 1994 and is based in Jeddah, the Kingdo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Country: Saudi Arabia
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4015

Financial Performance

In 2023, Jamjoom Pharmaceuticals Factory Company's revenue was 1.10 billion, an increase of 20.09% compared to the previous year's 916.67 million. Earnings were 292.40 million, an increase of 70.68%.